Sarah Goldberg

Aug 28, 2024 | nature.com | Michael J Peluso |Michelle Davidson |Sarah Goldberg |Jessica Chen |Badri Viswanathan |Kevin C. Donohue | +8 more

AbstractTo understand the roles of acute-phase viral dynamics and host immune responses in post-acute sequelae of SARS-CoV-2 infection (PASC), we enrolled 136 participants within 5 days of their first positive SARS-CoV-2 real-time PCR test. Participants self-collected up to 21 nasal specimens within the first 28 days post-symptom onset; interviewer-administered questionnaires and blood samples were collected at enrollment, days 9, 14, 21, 28, and month 4 and 8 post-symptom onset.

Jan 31, 2024 | newswise.com | Sarah Goldberg

Research Alert Non-small cell lung cancer (NSCLC), with an epidermal growth factor receptor (EGFR) mutation, tends not to respond well to immunotherapy treatments, including durvalumab. However, Yale Cancer Center (YCC) researchers recently reported in the Journal of Thoracic Oncology that the targeted therapy osimertinib, when administered after chemotherapy and radiation, is associated with significantly improved progression-free survival (living without the cancer worsening).

Sep 8, 2023 | newswise.com | Roy S. Herbst |Sarah Goldberg

Newswise — Although immunotherapies have shown promise in treating non-small cell lung cancer (NSCLC), many patients still do not respond well, and those who do may eventually develop resistance. In a new study, Yale Cancer Center researchers at Yale School of Medicine tested a new immunotherapy, NC318, in combination with the targeted immunotherapy, pembrolizumab (KEYTRUDA).

Jul 31, 2023 | nature.com | Sarah Goldberg

Innovative clinical trial designs with a patient-centered mission are crucial to advancing modern cancer care; the adaptive phase 2 umbrella study CTONG1702 provides one model for this new era of trial design. ‘Lung adenocarcinoma’, formerly a solitary entity in the histology-based categorization of non–small-cell lung cancer (NSCLC), now represents an ever-expanding list of diseases defined by molecular drivers.

Jul 21, 2023 | onclive.com | Sarah Goldberg

Sarah Goldberg, MD, MPH, associate professor, medical oncology, associate director, Medical Oncology-Hematology Program, research director, Center for Thoracic Cancers, chief, Thoracic Oncology, Yale School of Medicine, thoracic oncologist, Yale Cancer Center, Smilow Cancer Hospital, discusses the design and key objectives of an ongoing phase 1a/b study (NCT05374538) of VIC-1911 as a monotherapy and in combination with sotorasib (Lumakras) in KRAS G12C–mutant non–small cell lung cancer (NSCLC).